# Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy Canonical URL: https://biopharmsignal.com/news/SLDB/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-c4a8ff92 Ticker: SLDB Company: Solid Biosciences Source: Solid Biosciences Published: 2026-04-30 12:00 EST ## Summary - Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN,... ## Article Body - Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that multiple abstracts have been accepted for presentation at the upcoming 29 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11-15, 2026, in Boston, MA. Solid Biosciences will deliver its largest number of presentations for the Company, reflecting the growing breadth and depth of Solid’s scientific efforts spanning clinical development, next-generation delivery technologies, capsid engineering and scalable manufacturing. “With 16 Solid-led presentations, ASGCT 2026 marks an important meeting for the Company and reflects our growing leadership in next-generation precision genetic medicine,” said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences. “The number and diversity of presentations we will be sharing underscore how far our organization has progressed in three short years, in addition to the scientific rigor we’re applying across discovery, development, manufacturing and clinical translation. From advanced platform and delivery technology engineering to updates from our clinical programs, this body of work reflects both the ambition of our team and the increasing maturity of our science.” Oral Presentations Title: Update on the INSPIRE DUCHENNE Phase 1/2 Study of the Next-Generation Microdystrophin Gene Therapy Candidate SGT-003 for Duchenne Muscular Dystrophy Session: In vivo clinical trials in eye and muscle disorders Presentation ID: 502 Date/Time: May 15, 3:30pm ET Presenter: Kevin Flanigan, MD, Advisor Consultant & Researcher, Nationwide Children’s Hospital and Principal Investigator in the Phase 1/2 INSPIRE DUCHENNE clinical trial Title: Efficacy and Safety of a Novel Investigational AAV FXN Gene Therapy (SGT-212) for the Treatment of Friedreich’s Ataxia Session: Neurologic diseases V Presentation ID: 353 Date/Time: May 14, 10:30am ET Presenter: Brandon Chan, PhD, Discovery & Translational Development, Scientific Lead Title: Development and Implementation of a High Yield and Scalable Manufacturing Process for Adeno-Associated Virus (AAV) Production Session: Scale-up, scale-out, formulation, supply chains, quality, and logistics I Presentation ID: 246 Date/Time: May 13, 4:00pm ET Presenter: Ben Wright, Vice President, Head of Process Development Title: Boosting rAAV Yield in HEK293 Cells Through Multi-Mechanism Strategies Session: AAV transfection improvements: Scaling and titers Presentation ID: 320 Date/Time: May 14, 10:30am ET Presenter: Xiaofei E, PhD, Director, Molecular Therapeutics Title: Utilizing Machine Learning and Mechanistic Understanding to Appreciate the Impact of pH, Dissolved Oxygen, and pCO₂ on Upstream AAV Yield and Product Quality Session: AAV critical quality attributes Presentation ID: 263 Date/Time: May 14, 8:00am ET Presenter: Neil Templeton, PhD, Director, Upstream Process Development Poster Presentations Title: Novel Pharmacokinetic Effects of POLARIS-101™ (AAV-SLB101), Solid Biosciences’ Rationally Designed, Next-Generation Capsid Presentation ID: 3385 Presenter: Patrick Gonzalez, PhD, Vice President, Head of Clinical Science Title: SGT-003 Gene Therapy Restores DAPC Stability and Improves Muscle Integrity in Duchenne Muscular Dystrophy Presentation ID: 2365 Presenter: Jamie Marshall, PhD, Director and Scientific Lead, Discovery & Translational Development Title: A Novel AAV Gene Therapy Strategy to Correct Calcium Dysregulation in Catecholaminergic Polymorphic Ventricular Tachycardia Presentation ID: 1429 Presenter: Meghan Soustek-Kramer, PhD, Principal Scientist and Scientific Lead, Discovery & Translational Development Title: Systemic Delivery of Human TNNT2 Gene Therapy Using the Novel Capsid POLARIS-101™ (AAV-SLB101) Improves Cardiac Function in the TNNT2 R141W Knock-in Mouse Model of Dilated Cardiomyopathy Presentation ID: 3430 Presenter: Jamie Marshall, PhD, Director and Scientific Lead, Discovery & Translational Development Title: Systemic Administration of a Rationally Engineered Vector (POLARIS-101™ [AAV-SLB101]) Leads to Successful Transduction of Non-Human Primate Tissues in the Presence of Neutralizing Antibodies Presentation ID: 3397 Presenter: Kruti Patel, PhD, Associate Director and Scientific Lead, Discovery & Translational Development Title: Lower POLARIS-101 TM (AAV-SLB101) Cross-Reactive Antibodies in Elevidys-Treated Patients Presentation ID: 3382 Presenter: Marla Bazile, Principal Associate Scientist, R&D Title: Small Molecule Induced G2/M Arrest Boosts Recombinant AAV Production and Preserves High Quality Presentation ID: 3146 Presenter: Xiaofei E, PhD, Director, Molecular Therapeutics Title: Impact of Genome Size and Sequence Composition on AAV Vector Genome Integrity Presentation ID: 2010 Presenter: Jie Tan, PhD, Director, Predictive Sciences Title: Connecting Changes in AAV Capsid Protein Charge Species to In Vitro Protein Expression Presentation ID: 2216 Presenter: Jonathan Hill, PhD, Principal Scientist Title: Impact of Full vs. Empty AAV Capsids on Vector Potency Presentation ID: 2221 Presenter: Cristiano Vieira, PhD, Senior Scientist, Analytical Title: Identifying Sources of Library Preparation Artifacts in AAV Vectors with SMRT Sequencing Presentation ID: 1219 Presenter: Sarah Tong, Senior Associate Scientist, Analytical Development Additionally, Armatus Bio will present a poster highlighting POLARIS-101™’s utility in Facioscapulohumeral muscular dystrophy (FSHD) animal models: Title : FSHD Gene Therapy Using Systemic Delivery of Therapeutic miRNAs and the Engineered AAV-SLB101 Capsid Corrects FSHD-associated Phenotypes at Lower Doses Than First Generation Vectors Presentation ID : 1500 Presenter: Lindsay Wallace, PhD, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital About Solid Biosciences Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com . Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s goals; anticipated benefits of and strategies and expectations for the company’s SGT-003, SGT-212 and SGT-501 programs; expectations for planned enrollment of its SGT-003, SGT-212 and SGT-501 programs; planned regulatory interactions and the potential approval pathways for SGT-003; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs, capsid libraries and other enabling technologies on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; manufacture sufficient quantities of our drug product in a timely manner and maintain adequate supply to support our clinical development and potential commercialization; obtain, maintain or protect intellectual property rights related to its product candidates; replicate preliminary or interim data from clinicals trials in the final data of such trials; compete successfully with other companies that are seeking to develop Duchenne, FA, CPVT and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003, SGT-212, SGT-501, SGT-601 and other candidates; achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. Solid Biosciences Investor Contact: Nicole Anderson Senior Director, Investor Relations and Corporate Communications Solid Biosciences Inc. investors@solidbio.com ## Recent Company News - 2026-06-01 20:05 EST — [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-8b813e20) — Source: Solid Biosciences - 2026-06-01 12:00 EST — [Solid Biosciences to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-2a3e1bc2) — Source: Solid Biosciences - 2026-05-12 20:08 EST — [Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-busi-5df78103) — Source: Solid Biosciences - 2026-05-07 12:00 EST — [Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/SLDB/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-clinical-tr-0b3eb7cf) — Source: Solid Biosciences - 2026-05-01 20:05 EST — [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-e564b5de) — Source: Solid Biosciences ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)